Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

By Kang Myoung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1607-1613

Springer Publishing Company

Access to resources Recommend Favorite

Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer

By >   Pietrantonio Filippo   Martinetti Antonia   Buzzoni Roberto   Gevorgyan Arpine   Bajetta Emilio  

Drugs & Aging, Vol. 28, Iss. 2, 2011-02 ,pp. : 83-91

Adis International

Access to resources Recommend Favorite

Chemotherapy for Metastatic Colorectal Cancer

By Rosales Joseph   Leong Lucille A.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 3, Iss. 4, 2005-07 ,pp. : 525-529

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art

By  

Clinical Cancer Drugs, Vol. 1, Iss. 1, 2014-01 ,pp. : 78-83

Bentham Science Publishers

Access to resources Recommend Favorite

Bevacizumab: A Review of its Use in Metastatic Colorectal Cancer

By McCormack Paul L.   Keam Susan J.  

Drugs, Vol. 68, Iss. 4, 2008-01 ,pp. : 487-506

Adis International

Access to resources Recommend Favorite